https://doi.org/10.55788/5682a8ea
Iron plays a critical role in myelin formation and repair, as well as in neurodegenerative processes that occur in MS. However, the specific quantification of iron and myelin using MRI in vivo remains a challenge. The χ-separation is a novel biophysical model based on quantitative susceptibility mapping. It is a recently proposed method that allows for separate assessment of myelin and iron distribution in the brain. Dr Jannis Müller (University of Basel, Switzerland) and colleagues applied χ-separation to longitudinally distinguish between the contributions of iron and myelin to the susceptibility of MS lesions [1]. They applied the χ-separation to acquire multi-echo (T2*) and fast acquisition with spiral trajectory and adiabatic T2-prep (T2). This allowed them to generate myelin-sensitive and iron-sensitive susceptibility maps. FLAIR and MP2RAGE images were used to segment white matter lesions, cortical lesions, and surrounding normal-appearing tissue.
The researchers included 168 MS patients; 101 (64%) were women, the median age was 47.3 years, and the median EDSS score was 3.0. Of this group, 108 were followed up for a median of 2 years. At baseline, significant differences were found between lesions and surrounding normal-appearing tissue. After 2 years, changes in myelin content correlated with disability improvement, while iron levels overall remained stable. Remyelination was associated with:
- younger age (β=-5.111×10−5; aR2=0.003; P<0.001);
- lower disability (β=-2.664×10−4; aR2=0.001; P<0.001); and
- relapsing-remitting MS phenotype (compared with progressive MS, 0.0026 vs 0.0011; P<0.001).
Changes in myelin-sensitive susceptibility maps correlated with clinical improvement as measured by EDSS score (β=-6.686×10−4; aR2=0.004; P=0.015).
- Müller J, et al. Magnetic susceptibility source separation shows longitudinal changes in myelin and iron in white matter and cortical lesions in multiple sclerosis patients. P168, MSMilan 2023, 11–13 October, Milan, Italy.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Anti-CD40L antibody safe and effective in a phase 2 study Next Article
Early intensive treatment enhances long-term clinical outcomes »
« Anti-CD40L antibody safe and effective in a phase 2 study Next Article
Early intensive treatment enhances long-term clinical outcomes »
Table of Contents: MSMilan 2023
Featured articles
Letter from the Editor
Real-world data supports ocrelizumab prior to conception
Progressive MS
Early initiation of highly active treatment associated with a lower risk of SPMS
Ocrelizumab more effective than interferon/glatiramer acetate in older MS patients
Paediatric MS
Prioritising high efficacy therapies in children with MS
Omega-3 polyunsaturated fatty acids associated with lower risk of MS activity
NMOSD & MOGAD
An update on evolving treatment algorithms for NMOSD and MOGAD
Women’s Health
Rate of grey matter brain atrophy accelerates after menopause
Real-world data supports ocrelizumab prior to conception
Miscellaneous
New insights into the contribution of EBV to MS pathogenesis
COVID-19 infection associated with higher MS relapse rate
Telerehabilitation effective in improving MS symptoms in patients with moderate disability
Curing MS
Understanding what an MS cure means and what it takes
Prodromal MS
Progressive brain tissue loss precedes the onset of clinical MS by years
Sickness absence rate increases years before clinical onset of MS
Treatment Trials and MS Strategies
Early intensive treatment enhances long-term clinical outcomes
Oral glycolipid shows promise in the treatment of MS, especially SPMS
Fenebrutinib shows rapid reduction of new Gd+ T1 lesions
Challenges of de-escalation versus discontinuation of highly effective DMTs in older MS patients
Biomarkers & Imaging
χ-separation can assess the effects of tissue destruction in early MS lesions
High sGFAP levels are associated with disease progression, independent of NfL or relapse activity
Broad rim lesions correlate with a rapidly progressive MS phenotype
Smouldering inflammation detectable even in the earliest stages of MS
Related Articles
December 9, 2021
Long-term suppression of MRI disease activity with ocrelizumab
November 25, 2020
‘Reassuring’ data on cancer risk in people with multiple sclerosis
September 10, 2020
Eculizumab in NMOSD: the PREVENT study
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com